HGS Wastes No Time Investing In Pipeline Beyond Benlysta
This article was originally published in The Pink Sheet Daily
Executive Summary
One week after receiving FDA approval for its breakthrough lupus drug, Human Genome Sciences is spending $50 million for broad rights to an early-stage cancer drug that hits a popular target.
You may also be interested in...
GSK And HGS Face Off Over Buyout
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.